{ "labelLang" : "eng", "responseDate" : "2024-03-29 15:58", "content" : { "otype" : "BookChapter", "mtid" : 25477356, "status" : "ADMIN_APPROVED", "published" : true, "unhandledTickets" : 0, "oldTimestamp" : "2016-03-05T15:15:53.000+0000", "deleted" : false, "oldId" : 15477356, "lastRefresh" : "2024-03-12T17:59:21.428+0000", "lastModified" : "2024-03-12T17:58:04.371+0000", "created" : "2016-03-05T15:14:07.000+0000", "creator" : { "otype" : "Author", "mtid" : 10023751, "link" : "/api/author/10023751", "label" : "Irén Haltrich (Biológia genetika)", "familyName" : "Haltrich", "givenName" : "Irén", "published" : true, "oldId" : 10023751, "snippet" : true }, "lastDuplumSearch" : "2024-03-20T17:36:41.093+0000", "adminApproved" : "2016-03-05T15:15:53.000+0000", "adminApprover" : { "otype" : "Admin", "mtid" : 10019974, "link" : "/api/admin/10019974", "label" : "Ferencné Szűts (SE_AOK_2Gyerek_Admin5_SzFné, admin)", "familyName" : "Szűts", "givenName" : "Ferencné", "published" : true, "oldId" : 10019974, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Chapter in Book", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000398, "link" : "/api/subtype/10000398", "label" : "Chapter (Chapter in Book)", "name" : "Könyvfejezet", "nameEng" : "Chapter", "docType" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Chapter in Book", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "listPosition" : 220, "published" : true, "oldId" : 10000398, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Scientific", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "English", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Mukaetova-Ladinska, EB", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 45666856, "link" : "/api/authorship/45666856", "label" : "Mukaetova-Ladinska, EB", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "Mukaetova-Ladinska", "givenName" : "EB", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Author", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 80270601, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 45666857, "link" : "/api/authorship/45666857", "label" : "Perry, EK", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : true, "familyName" : "Perry", "givenName" : "EK", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Author", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 80270600, "snippet" : true } ], "title" : "Molecular basis of cholinergic changes in autism spectrum disorders and relevance for treatment interventions", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 10508656, "link" : "/api/publicationidentifier/10508656", "label" : "DOI: 10.1007/978-1-4939-2190-4_15", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1007/978-1-4939-2190-4_15", "realUrl" : "https://doi.org/10.1007/978-1-4939-2190-4_15", "published" : false, "oldId" : 11473197, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 10508655, "link" : "/api/publicationidentifier/10508655", "label" : "Scopus: 84944578273", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "84944578273", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-84944578273", "published" : false, "oldId" : 11473196, "snippet" : true } ], "firstPage" : "307", "lastPage" : "335", "firstPageOrInternalIdForSort" : "307", "pageLength" : 29, "publishedYear" : 2015, "digital" : null, "printed" : null, "sourceYear" : 2016, "packet" : "(Szűts Ferencné (SE_AOK_Adm5_2Gyerek_SzF...); 2016.03.05. 16:13:00)", "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2024-03-12", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 2, "citedCount" : 2, "referenceList" : "Abdallah, M.W., Mortensen, E.L., Greaves-Lord, K., Larsen, N., Bonefeld-Jorgensen, E.C., Norgaard-Pedersen, B., Hougaard, D.M., Grove, J., Neonatal levels of neurotrophic factors and risk of autism spectrum disorders (2012) Acta Psychiatr Scand, 128, pp. 61-69; \n\nAbrams, P., Andersson, K.E., Buccafusco, J.J., Chapple, C., de Groat, W.C., Fryer, A.D., Kay, G., Wein, A.J., Muscarinic receptors: Their distribution and function in body systems, and the implications for treating overactive bladder (2006) Br J Pharmacol, 148, pp. 565-578; \n\nAcevido, N.L., Muralidharan, B., Paadala, N., To, J., Jonakait, G.M., Toll-like receptor ligands and CD154 stimulate microglia to produce a factor(s) that promote excess cholinergic differentiation in the developing rat basal forebrain: Implications for neurodevelopmental disorders (2007) Pediatr Res, 61, pp. 15-20; \n\nAdams, C.E., Yonchek, J.C., Schulz, K.M., Graw, S.L., Stitzel, J., Teschke, P.U., Stevens, K.E., Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: Implications for neuropsychiatric diseases (2012) Neuroscience, 207, pp. 274-282; \n\nAhmed, A.I., Ali, A.N., Kramers, C., Härmark, L.V., Burger, D.M., Verhoeven, W.M., Neuropsychiatric adverse events of varenicline: A systematic review of published reports (2013) J Clin Psychopharmacol, 33, pp. 55-62; \n\nAlkondon, M., Albuquerque, E.X., The nicotinic acetylcholine receptor subtypes and their function in the hippocampus and cerebral cortex (2004) Prog Brain Res, 145, pp. 109-120; \n\nAmenta, F., Tayebati, S.K., Pathways of acetylcholine synthesis, transport and release as targets for treatment of adult-onset cognitive dysfunction (2008) Curr Med Chem, 15, pp. 488-498; \n\n(2000) Diagnostic and statistical manual of mental disorders, , (4th ed., text revision). Washington, DC: American Psychiatric Association; \n\nAnthenelli, R.M., Morris, C., Ramey, T.S., Dubrava, S.J., Tsilkos, K., Russ, C., Yunis, C., Effects of varenicline on smoking cessation in aduts with stably treated current or past major depression: A randomized control trial (2013) Ann Int Med, 159, pp. 390-400; \n\nArnold, L.E., Aman, M.G., Hollway, J., Hurt, E., Bates, B., Li, X., Farmer, C., Williams, C., Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders (2012) J Child Adolesc Psychopharmacol, 22, pp. 198-205; \n\nArnold, L.E., Anand, R., Aman, M., Varenicline in autistic disorder: Hypothesis and case report of single-patient crossover (2013) J Child Adolesc Psychopharmacol, 23, pp. 61-64; \n\nAuld, D.S., Kornecook, T.J., Bastianetto, S., Quirion, R., Alzheimer’s disease and the basal forebrain cholinergic system: Relations to beta-amyloid peptides, cognition, and treatment strategies (2002) Prog Neurobiol, 68, pp. 209-245; \n\nAylward, E.H., Minshew, N.J., Field, K., Sparks, B.F., Singh, N., Effects of age on brain volume and head circumference in autism (2002) Neurology, 59, pp. 175-183; \n\nBailey, C.D., De Biasi, M., Fletcher, P.J., Lambe, E.K., The nicotinic acetylcholine receptor alpha5 subunit plays a key role in attention circuitry and accuracy (2010) J Neurosci, 30, pp. 9241-9252; \n\nBailey, C.D., Alves, N.C., Nashmi, R., De Biasi, M., Lambe, E.K., Nicotinic a5 subunits drive developmental changes in the activation and morphology of prefrontal cortex layer VI neurons (2012) Biol Psychiatry, 71, pp. 120-128; \n\nBaulac, S., Huberfeld, G., Gourfinkel-An, I., Mitropoulou, G., Beranger, A., Prud’homme, J.F., Baulac, M., LeGuerm, E., First genetic evidence of GABA9A receptor dysfunction in epilepsy: A mutation in the gamma-2-subunit gene (2001) Nat Genet, 28, pp. 46-48; \n\nBauman, M.L., Kemper, T.L., Neuroanatomical observations of the brain in autism (1994) The Neurobiology of Autism, pp. 119-145. , Bauman ML, Kemper TL (eds), The Johns Hopkins University Press, Baltimore; \n\nBernardi, S., Anagnostou, E., Shen, J., Kolevzon, A., Buxbaum, J.D., Hollander, E., Hof, P.R., Fan, J., In vivo 1H-magnetic resonance spectroscopy study of the attentional networks in autism (2011) Brain Res, 1380, pp. 198-205; \n\nBlumberg, S.J., Bramlett, M.D., Kogan, M.D., Schive, L.A., Jones, J.R., Lu, M.C., Changes in prevalence of parent-reported autism spectrum disorder in school-aged US children: 2007 to 20112012 (2013) Nat Heath Stat Reports, 65, pp. 1-12; \n\nBrugha, T.S., McManus, S., Bankart, J., Scott, F., Purdon, S., Smith, J., Bebbington, P., Meltzer, H., Epidemiology of autism spectrum disorders in adults in the community in England (2011) Arch Gen Psychiatry, 68, pp. 459-465; \n\nBuckley, A.W., Sassower, K., Rodriguez, A.J., Jennison, K., Wingert, K., Buckley, J., Thurm, A., Swedo, S., An open label trial of donepezil for enhancement of rapid eye movement sleep in young children with autism spectrum disorders (2011) J Child Adolesc Psychopharmacol, 21, pp. 353-357; \n\nBuiter, H.J., Windhorst, A.D., Huisman, M.C., Yaqub, M., Knol, D.L., Fisher, A., Lammertsma, A.A., Leysen, J.E., (2013), 23, p. 19Cavarsan, C.F., Avanzi, R.D., Queiroz, C.M., Xavier, G.F., Mello, L.E., Covolan, L., M1 acetylcholine receptor expression is decreased in hippocampal CA1 region of aged epileptic animals (2011) Aging Dis, 2, pp. 301-307; \n\nPrevalence of autism spectrum disorders-autism and developmental disabilities monitoring network, 14 sites. United States, 2008 (2012) MMWR, 61, pp. 1-19; \n\nCheng, S.B., Amici, S.A., Ren, X.Q., McKay, S.B., Treuil, M.W., Lindstrom, J.M., Rao, J., Anand, R., Presynaptic targeting of alpha4beta 2 nicotinic acetylcholine receptors is regulated by neurexin-1beta (2009) J Biol Chem, 284, pp. 23251-23259; \n\nChez, M.G., Buchanan, T.M., Becker, M., Kessler, J., Aimonovitch, M.C., Mrazek, S.R., Donepezil hydrochloride: A double-blind study in autistic children (2003) J Pediatric Neurol, 1, pp. 83-88; \n\nChez, M.G., Aimonovitch, M., Buchanan, T., Meazek, S., Tremb, R.J., Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate (2004) J Child Neurol, 19, pp. 165-169; \n\nChilian, B., Abdollahpour, H., Bierhals, T., Haltrich, I., Fekete, G., Nagel, I., Rosenberger, G., Kutsche, K., Dysfunction of SHANK2 and CHRNA7 in a patient with intellectual disability and language impairment supports genetic epistasis of the two loci (2013) Clin Genet, 84, pp. 560-565; \n\nChung, Y.C., Lee, C.R., Park, T.W., Yang, K.H., Kim, K.W., Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial (2009) World J Biol Psychiatry, 10, pp. 156-162; \n\nConstantino, J.N., The quantitative nature of autistic social impairment (2011) Pediatric Res, 69, p. 5562; \n\nCourchesne, E., Karus, C.M., Davis, H.R., Ziccardi, R., Carper, R.A., Tigue, Z.D., Chisum, H.J., Courchesne, R.Y., Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study (2001) Neurology, 57, pp. 245-253; \n\nCroen, L.A., Goines, P., Braunschweig, D., Yolken, R., Yoshida, C.K., Grether, J.K., Fireman, B., Van de Water, J., Brain-derived neurotrophic factor and autism: Maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) Study (2008) Autism Res, 1, pp. 130-137; \n\nCubells, J.F., Deoreo, E.H., Harvey, P.D., Garlow, S.J., Garber, K., Adam, M.P., Martin, C.L., Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome (2011) Am J Med Genet A, 155, pp. 805-810; \n\nCulp, D.J., Luo, W., Richardson, L.A., Watson, G.E., Latchney, L.R., Both M1 and M3 receptors regulate exocrine secretion by mucous acini (1996) Am J Physiol Cell Physiol, 271, pp. C1963-C1972; \n\nde Caires, S., Steenkamp, V., Use of Yokukansan (TJ-54) in the treatment of neurological disorders: A review (2010) Phytother Res, 24, pp. 1265-1270; \n\nDe Vitto, T.J., Drost, D.J., Neufeld, R.W.J., Rajakumar, N., Pavlosky, W., Williamson, P., Nicolson, R., Evidence for cortical dysfunction in autism: A proton magnetic resonance spectroscopic imaging study (2007) Biol Psychiatry, 61, pp. 465-473; \n\nDeng, C., Huang, X.F., Decreased density of muscarinic receptors in the superior temporal gyrus in schizophrenia (2005) J Neurosci Res, 81, pp. 883-890; \n\nDeutsch, S.I., Urbano, M.R., Burket, J.A., Herndon, A.L., Winebarger, E.E., Pharmacotherapeutic implications of the association between genomic instability at chromosome 15q13.3 and autism spectrum disorders (2011) Clin Neuropharmacol, 34, pp. 203-205; \n\nDwyer, J.B., Broide, R.S., Leslie, F.M., Nicotine and brain development (2008) Brain Defects Res (PC), 84, pp. 30-44; \n\nFarlow, M., Miller, M.L., Pejovic, V., Treatment options in Alzheimer’s disease: Maximizing benefit, managing expectations (2008) Dement Geriatr Cogn Disord, 25, pp. 408-422; \n\nFatemi, S.H., Yousefi, M.K., Kneeland, R.E., Liesch, S.B., Folsom, T.D., Thiras, P.D., Antismoking and potential antipsychotic effects of varenicline in subjects with schizophrenia or schizoaffective disorder: A double-blind placebo and buroprion-controlled study (2013) Schizophr Res, 146, pp. 376-378; \n\nFelder, C.C., Bymaster, F.P., Ward, J., DeLapp, N., Therapeutic opportunities for muscarinic receptors in the central nervous system (2000) J Med Chem, 43, pp. 4333-4353; \n\nFernandes, C.C., Pinto-Duartes, A., Ribiero, J.A., Sebastiao, A.M., Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons (2008) J Neurosci, 21, pp. 5611-5618; \n\nGabis, L., Huang, W., Azizian, A., DeVincent, C., Tudorica, A., Kesner-Baruch, Y., Roche, P., Pomeroy, J., 1H-magnetic resonance spectroscopy markers of cognitive and language ability in clinical subtypes of autism spectrum disorders (2008) J Child Neurol, 23, pp. 766-774; \n\nGarcia, K.L., Yu, G., Nicolini, C., Michalski, B., Garzon, D.J., Chiu, V.S., Tongiorgi, E., Fahnestock, M., Altered balance of proteolytic isoforms of pro-brain-derived neurotrophic factor in autism (2012) J Neuropathol Exp Neurol, 71, pp. 289-297; \n\nGaynor, C.M., Handley, S.L., Effects of nicotine on head-shakes and tryptophan metabolites (2001) Psychopharmacol, 153, pp. 327-333; \n\nGhaleiha, A., Ghyasvand, M., Mohammadi, M.R., Farokhnia, M., Yadegari, N., Tabrizi, M., Hajiaghaee, R., Akhondzadeh, S., Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial (2013) J Psychopharmacol, 28, pp. 677-685; \n\nGibbons, R.D., Mann, J.J., Varenicline, smoking cessation, and neuropsychiatric adverse events (2013) Am J Psychiatry, 170, pp. 1-8; \n\nGillberg, C., Billstedt, E., Autism and Asperger syndrome: Coexistence with other clinical disorders (2000) Acta Psychiat Scand, 102, pp. 321-330; \n\nGotti, C., Zoli, M., Clementi, F., Brain nicotinic acetylcholine receptors: Native subtypes and their relevance (2006) Trends Pharmacol Sci, 27, pp. 482-491; \n\nGranon, S., Faure, P., Changeux, J.P., Executive and social behaviors under nicotinic receptor regulation (2003) Proc Natl Acad Sci USA, 100, pp. 9596-9691; \n\nHanden, B.L., Johnson, C.R., McAuliffe-Bellin, S., Murray, P.J., Hardan, A.Y., Safety and efficacy of donepezil in children and adolescents with autism: Neuropsychological measures (2011) J Child Adolesc Psychopharmacol, 21, pp. 43-50; \n\nHardan, A.Y., Handen, B.L., A retrospective open trial of adjunctive donepezil in children and adolescents with autistic disorder (2002) J Child Adolesc Psychopharmacol, 12, pp. 237-241; \n\nHardan, A.Y., Minshew, N.J., Melhem, N.M., Srihari, S., Jo, B., Bansal, R., Leshavan, M.S., Stanley, J.A., An MRI and proton spectroscopy study of the thalamus in children with autism (2008) Psychiatry Res, 163, pp. 97-105; \n\nHashimoto, K., Iwata, Y., Nakamura, K., Tsujii, M., Tsuchiya, K., Sekine, Y., Suzuki, K., Mori, N., Reduced serum levels of brain-derived neurotrophic factor in adult male patients with autism (2006) Prog Neuropsychophramacol Biol Psychiatry, 30, pp. 1529-1531; \n\nHazlett, H.C., Poe, M.D., Lightbody, A.A., Styner, M., MacFall, J.R., Reiss, A.L., Piven, J., Trajectories of early brain volume development in fragile X syndrome and autism (2012) J Am Acad Child Adolesc Psychiatry, 51, pp. 921-933; \n\nHeller, J.H., Spiridigliozzi, G.A., Dorraiswamy, P.M., Sullivan, J.A., Crissman, B.G., Kishnani, P.S., Donepezil effects on language in children with Down syndrome: Results of the first 22-week pilot clinical trial (2004) Am J Med Genet, 130 A, pp. 325-356; \n\nHeller, J.H., Spiridigliozzi, G.A., Crissman, B.G., Sullivan, J.A., Eelis, R.L., Li, J.S., Doraiswamy, P.M., Kishnani, P.S., Safety and efficacy of rivastigmine in adolescents with down syndrome: A preliminary 20-week, open-label study (2006) J Child Adolesc Psychopharmacol, 16, pp. 755-765; \n\nHeller, J.H., Spiridigliozzi, G.A., Crissman, B.G., McKillop, J.A., Yamamoto, H., Kishnani, P.S., Safety and efficacy of rivastigmine in adolescents with Down syndrome: Long-term follow-up (2010) J Child Adolesc Psychopharmacol, 20, pp. 517-520; \n\nHerbert, M.R., Ziegler, D.A., Makris, N., Filipek, P.A., Kemper, T.L., Normandin, J.J., Sanders, H.A., Caviness, V.S., Jr., Localization of white matter volume increase in autism and developmental language disorder (2004) Ann Neurol, 55, pp. 530-540; \n\nHertzman, M., Galantamine in the treatment of adult autism: A report of three clinical cases (2003) Int J Psychiatry Medicine, 33, pp. 395-398; \n\nHillmer, A.T., Wooten, D.W., Slesarev, M.S., Ahlers, E.O., Barnhart, T.E., Murali, D., Schneider, M.L., Christian, B.T., PET imaging of a4ß2* nicotinic acetylcholine receptors: Quantitative analysis of 18F-nifene kinetics in the nonhuman primate (2012) J Nucl Med, 53, pp. 1471-1480; \n\nHillmer, A.T., Wooten, D.W., Farhoud, M., Barnhart, T.E., Mukherjee, J., Christian, B.T., The effects of lobeline on a4ß2* nicotinic acetylcholine receptor binding and uptake of [18F]nifene in rats (2013) J Neurosci Methods, 214, pp. 163-169; \n\nHohmann, C.F., Berger-Sweeney, J., Cholinergic regulation of cortical development and plasticity: New twists to an old story (1998) Perspect Dev Neurobiol, 5, pp. 401-425; \n\nHohnadel, E., Bouchard, K., Terry, A.V., Jr., Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats (2007) Neuropharmacology, 52, pp. 542-551; \n\nHoughton, P.J., Ren, Y., Howes, M.J., Acetylcholinesterase inhibitors from plants and fungi (2006) Nat Prod Rep, 23, pp. 181-199; \n\nHowson, A.L., Batth, S., Ilivitsky, V., Boisjoli, A., Jaworski, M., Mahoney, C., Knott, V.J., Clinical and attentional effects of acute nicotine treatment in Tourette’s syndrome (2004) Eur Psychiatry, 19, pp. 102-112; \n\nHuh, C.Y.L., Danik, M., Manseau, F., Trudeau, L.-E., Williams, S., Chronic exposure to nerve growth factor increases acetylcholine and glutamate release from cholinergic neurons of the rat medial septum and diagonal band of Broca via Mechanisms mediated by p75NTR (2008) J Neurosci, 28, pp. 1404-1409; \n\nJamain, S., Betancur, C., Quach, H., Philippe, A., Fellous, M., Giros, B., Gillberg, C., Bourgeron, T., Linkage and association of the glutamate receptor 6 gene with autism (2002) Mol Psychiatry, 7, pp. 302-310. , Study PARISP; \n\nJames, S.J., Pauly, M., Melnyk, S., Stewart, P.A., Schmidt, B.L., Lemcke, N., Reynolds, A.M., Hyman, S.L., (2011) Dietary choline intake by children with autism is below the recommended dietary reference intake (DRI) established by the IOM, , International meeting for autism research: dietary choline intake by children with autism is below the recommended dietary reference intake (DRI) established by the IOM INSAR meeting, 11 May 2011; \n\nKang, K., Huang, X.F., Wang, Q., Deng, C., Decreased density of serotonin 2A receptors in the superior temporal gyrus in schizophrenia-a postmortem study (2009) Prog Neuropsychopharmacol Biol Psychiatry, 33, pp. 867-871; \n\nKarvat, G., Kimchi, T., Acetylcholine elevation relieves cognitive rigidity and social deficiency in a mouse model of autism (2013) Neuropsychopharmacology, 39, pp. 831-840; \n\nKatoh-Semba, R., Wakako, R., Komori, T., Shigemi, H., Miyazaki, N., Ito, H., Kumagai, T., Nakayama, A., Age-related changes in BDNF protein levels in human serum: Differences between autism cases and normal controls (2007) Int J Dev Neurosci, 25, pp. 367-372; \n\nKawai, H., Zago, W., Berg, D.K., Nicotinic a7 receptor clusters on hippocampal GABAergic neurons: Regulation by synaptic activity and neurotrophins (2002) J Neurosci, 22, pp. 7903-7912; \n\nKawashima, K., Fujii, T., Moriwaki, Y., Misawa, H., Horiguchi, K., Reconciling neuronally and nonneuronally derived acetylcholine in the regulation of immune function (2012) Ann NY Acad Sci, 1261, pp. 7-17; \n\nKennedy, D.O., Wake, G., Savelev, S., Tildesley, N.T., Perry, E.K., Wesnes, K.A., Scholey, A.B., Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties (2003) Neuropsychopharmacology, 28, pp. 1871-1881; \n\nKishnani, P.S., Heller, J.H., Spiridigliozzi, G.A., Lott, I., Escobar, L., Richardson, S., Zhang, R., McRae, T., Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10-17 (2010) Am J Med Genet A, 152 A, pp. 3028-3035; \n\nKoshimizu, H., Leiter, L.M., Miyakawa, T., M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition (2012) Mol Brain, 5, p. 10; \n\nKrasnoperova, M.G., Simashkova, N.V., Bashina, V.M., Use of cholinomimetics in the treatment of endogeneous autism in children (2004) Zh Nevrol Psikhiatr Im S S Korsakova, 104, pp. 35-39; \n\nKroker, K.S., Rast, G., Rosenbrock, H., Differential effects of subtype-specific nicotinic acetylcholine receptor agonists on early and late hippocampal LTP (2011) Eur J Pharmacol, 671, pp. 26-32; \n\nLamping, K.G., Wess, J., Cui, Y., Nuno, D.W., Faraci, F.M., Muscarinic (M) receptors in coronary circulation: Gene-targeted mice define the role of M2 and M3 receptors in response to acetylcholine (2004) Arterioscler Thromb Vasc Biol, 24, pp. 1253-1258; \n\nLauder, J.M., Schambra, U.B., Morphogenetic roles of acetylcholine (1999) Environ Health Perspect, 107, pp. 65-69; \n\nLavine, N., Reuben, M., Clarke, P.B., A population of nicotinic receptors is associated with thalamocortical afferents in the adult rat: Laminal and areal analysis (1997) J Comp Neurol, 380, pp. 175-190; \n\nLe Couteur, A., Bailey, A., Goode, S., Pickles, A., Robertson, S., Gottesman, I., Rutter, M., A broader phenotype of autism: The clinical spectrum in twins (1996) J Child Psychol Psychiatry, 37, pp. 785-801; \n\nLee, M., Martin-Ruiz, C.M., Graham, A.J., Court, J.A., Jaros, E., Perry, R.H., Iverson, P., Perry, E.K., Nicotinic receptor abnormalities in the cerebellar cortex in autism (2002) Brain, 125, pp. 1483-1495; \n\nLevin, E.D., Caldwell, D.P., Low-dose mecamylamine improves learning of rats in the radialarm maze repeated acquisition procedure (2006) Neurobiol Learn Mem, 86, pp. 117-122; \n\nLevinson, D.F., Shi, J., Wang, K., Oh, S., Riley, B., Pulver, A.E., Wildenauer, D.B., Holmans, P.A., Genome-wide association study of multiplex schizophrenia pedigrees (2012) Am J Psychiatry, 169, pp. 963-973; \n\nLevy, R.B., Reyes, A.D., Aoki, C., Chollinergic modulation of local pyramid-interneuron synapses exhibiting divergent short-term dynamics in rat sensory cortex (2008) Brain Res, 1215, pp. 97-104; \n\nLewine, J.D., Andrews, R., Chez, M., Patil, A.A., Devinsky, O., Smith, M., Kanner, A., Orrison, W.W., Jr., Magnetoen-cephalographic patterns of epileptiform activity in children with regressive autism spectrum disorders (1999) Pediatrics, 104, pp. 405-418; \n\nLippiello, P.M., Nicotinic cholinergic antagonists: A novel approach for the treatment of autism (2005) Med Hypotheses, 66, pp. 985-990; \n\nMancama, D., Arranz, M.J., Landau, S., Kerwin, R., Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia (2003) Am J Med Genet B Neuropsychiatr Genet, 119 B, pp. 2-6; \n\nMariani, J., Extent of multiple innervation of Purkinje cells by climbing fibres in the olivocerebellar system of weaver, reeler, and staggerer mutant mice (1982) J Neurobiol, 13, pp. 119-126; \n\nMartin-Ruiz, C.M., Lee, M., Perry, R.H., Bauman, M.L., Court, J.A., Perry, E.K., Molecular analysis of nicotinic receptor expression in autism (2004) Brain Res Brain Mol Res, 123, pp. 81-90; \n\nMassey, K.A., Zago, W.M., Berg, D.K., BDNF up-regulates a7 nicotinic acetylcholine receptor levels on subpopulations of hippocampal interneurons (2006) Mol Cell Neurosci, 33, p. 8; \n\nMatsui, M., Motomura, D., Karasawa, H., Fujikawa, T., Jiang, J., Komiya, Y., Takahashi, S., Taketo, M.M., Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype (2000) Proc Natl Acad Sci USA, 97, pp. 9579-9584; \n\nMetherte, R., Nicotinic acetylcholine receptors in sensory cortex (2004) Learn Memory, 11, pp. 50-59; \n\nMills Schumann, C., Hamstra, J., Goodlin-Jones, B.L., Lotspeich, L.J., Kwon, H., Buonocore, M.H., Lammers, C.R., Amaral, D.G., The amygdala is enlarged in children but not adolescents with autism; the hippocampus is enlarged at all ages (2004) J Neurosci, 24, pp. 6392-6401; \n\nMills, J.L., Hediger, M.L., Molloy, C.A., Chrousos, G.P., Manning-Courtney, P., Yu, K.F., Brasington, M., England, L.J., Elevated levels of growth-related hormones in autism and autism spectrum disorder (2007) Clin Endocrinol, 67, pp. 230-237; \n\nMinshew, N.J., Sweeney, J.A., Bauman, M., Neurological aspects of autism (1997) Handbook of autism and pervasive developmental disorders, pp. 344-369. , Cohen D, Volkmar F (eds), Wiley, New York; \n\nMöller, J.C., Eggert, K.M., Unger, M., Odin, P., Chaudhuri, K.R., Oertel, W.H., Clinical risk-benefit assessment of dopamine agonists (2008) Eur J Neurol, 15, pp. 15-23; \n\nMowla, A., Mosavinasab, M., Haghshenas, H., Borhani Haghighi, A., Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer’s disease. A double-blind, placebo-controlled clinical trial (2007) J Clin Psychopharmacol, 27, pp. 484-487; \n\nMukaetova-Ladinska, E.B., Arnold, H., Jaros, E., Perry, R., Perry, E., Depletion of MAP2 expression and laminar cytoarchitectonic changes in dorsolateral prefrontal cortex in adult autistic individuals (2004) Neurobiol Appl Neurol, 30, pp. 615-623; \n\nMukaetova-Ladinska, E.B., Westwood, J., Perry, E.K., Cholinergic components in autism spectrum disorder (2010) The neurochemical basis autism, pp. 129-161. , From Molecules to Minicolumns, Blatt E (ed), Springer, Heidelberg; \n\nMukaetova-Ladinska, E.B., Schaffer, W., Bronnikova, T.V., Westwood, J., Perry, E.K., Cholinergic therapy for autistic spectrum disorder (2012) Cholinesterase: Production, uses and health effects, pp. 33-66. , White CJ, Tait JE (eds), Nova Science, New York; \n\nMulley, J.C., Mefford, H.C., Epilepsy and the new cytogenetics (2011) Epilepsia, 52, pp. 423-432; \n\nMurphy, M., Bolton, P.F., Pickles, A., Fombonne, E., Piven, J., Rutter, M., Personality traits of the relatives of autistic probands (2000) Psychol Med, 30, pp. 1411-1424; \n\nNathanson, N.M., Synthesis, trafficking, and localization of muscarinic acetylcholine receptors (2008) Pharmacol Ther, 119, pp. 33-43; \n\nNelson, K.B., Grether, J.K., Croen, L.A., Dambrosia, J.M., Dickens, B.F., Hansen, R.L., Phillips, T.M., Neuropeptides and neurotrophins in neonatal blood of children with autism, mental retardation and cerebral palsy (2000) Neurology, 54, p. A247; \n\nNelson, P.G., Kuddo, T., Song, E.Y., Dambrosia, J.M., Kohler, S., Satyanarayana, G., Vandunk, C., Nelson, K.B., Selected neurotrophins, neuropeptides, and cytokines: Developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome (2006) Int J Dev Neurosci, 24, pp. 73-80; \n\nNicolson, R., Craven-Thuss, B., Smith, J., A prospective, open-label trial of galantamine in autistic disorder (2006) J Child Adolesc Psychopharmacol, 16, pp. 621-629; \n\nNiederhofer, H., Staffen, W., Mair, A., Galantamine may be effective in treating autistic disorder (2002) BMJ, 32, p. 1422; \n\nPalma, E., Conti, L., Roseti, C., Limatola, C., Novel approaches to study the involvement of a7-nAChR in human diseases (2012) Curr Drug Targets, 13, pp. 579-586; \n\nPalmen, S.M.J.C., Hulshoff Pol, H.E., Kemner, C., Schnack, H.G., Durston, S., Lahuis, B.E., Kahn, R.S., van Engeland, H., Increased gray-matter volume in medication-naive high-functioning children with autism spectrum disorder (2004) Psychol Med, 34, pp. 1-10; \n\nPandey, S.K., Pan, S., Kant, R., Kuruvilla, S.A., Pan, M.L., Mukherjee, J., Synthesis and evaluation of 3-123I-iodo-5-[2-(S)-3-pyrrolinylmethoxy]-pyridine (niodene) as a potential nicotinic a402 receptor imaging agent (2012) Bioorg Med Chem Lett, 22, pp. 7610-7614; \n\nPennell, P.B., Burdette, D.E., Ross, D.A., Henry, T.R., Albin, R.L., Sackellares, J.C., Frey, K.A., Muscarinic receptor loss and preservation of presynaptic cholinergic terminals in hippocampal scelrosis (1999) Epilepsia, 40, pp. 38-46; \n\nPepeu, G., Giovannini, M.G., Changes in acetylcholine extracellular levels during cognitive processes (2004) Learn Memory, 11, pp. 21-27; \n\nPerry, E.K., Lee, M., Martin-Ruiz, C.M., Court, J.A., Volsen, S.G., Merrit, J., Folly, E., Wenk, G.L., Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain (2001) Am J Psychiatry, 158, pp. 1058-1066; \n\nPetersen, A.K., Ahmad, A., Shafiq, M., Brown-Kipphut, B., Fong, C.T., Anwar Iqbal, M., Deletion 1q43 encompassing only CHRM3 in a patient with autistic disorder (2013) Eur J Med Genet, 56, pp. 118-122; \n\nPickles, A., Starr, E., Kazak, S., Bolton, P., Papanikolaou, K., Bailey, A., Goodman, R., Rutter, M., Variable expression of the autism broader phenotype: Findings from extended pedigrees (2000) J Child Psychol Psychiatry, 41, pp. 491-502; \n\nRagozzino, M.E., Artis, S., Singh, A., Twose, T.M., Beck, J.E., Messer, W.S., Jr., The selective M1 muscarinic cholinergic agonist CDD-0102A enhances working memory and cognitive flexibility (2012) J Pharmacol Exp Ther, 340, pp. 588-594; \n\nRay, M.A., Graham, A.J., Lee, M., Perry, R.H., Court, J.A., Perry, E.K., Neuronal nicotinic acetylcholine receptor subunits in autism: An immunohistochemical investigation in the thalamus (2005) Neurobiol Dis, 19, pp. 366-377; \n\nRibeiz, S.R., Bassitt, D.P., Arrais, J.A., Avila, R., Steffens, D.C., Bottino, C.M., Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: A review and meta-analysis of the literature (2010) CNS Drugs, 24, pp. 303-317; \n\nRiley, B., Williamson, M., Collier, D., Wilkie, H., Makoff, A., A 3-Mb map of a large Segmental duplication overlapping the alpha7-nicotinic acetylcholine receptor gene (CHRNA7) at human 15q13-q14 (2002) Genomics, 79, pp. 197-209; \n\nRotering, S., Scheunemann, M., Fischer, S., Hiller, A., Peters, D., Deuther-Conrad, W., Brust, P., Radiosynthesis and first evaluation in mice of [(18)F]NS14490 for molecular imaging of a7 nicotinic acetylcholine receptors (2013) Bioorg Med Chem, 21, pp. 2635-2642; \n\nRubenstein, J.L., Merzenich, M.M., Model of autism: Increased ratio of excitation/inhibition in key neural systems (2003) Genes Brain Behav, 2, pp. 255-267; \n\nSadakata, T., Shinoda, Y., Oka, M., Sekine, Y., Sato, Y., Saruta, C., Miwa, H., Furuichi, T., Reduced axonal localization of a Caps2 splice variant impairs axonal release of BDNF and causes autistic-like behavior in mice (2012) Proc Natl Acad Sci U S A, 109, pp. 21104-21109; \n\nScarr, E., Sundram, S., Keriakous, D., Dean, B., Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia (2007) Biol Psychiatry, 61, pp. 1161-1170; \n\nScholey, A.B., Tildesley, N.T., Ballard, C.G., Wesnes, K.A., Tasker, A., Perry, E.K., Kennedy, D.O., An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers (2008) Psychopharmacology (Berl), 198, pp. 127-139; \n\nSheikh, A.M., Malik, M., Wen, G., Chauhan, A., Chauhan, V., Gong, C.X., Liu, F., Li, X., BDNF-Akt-Bc12 antiapoptotic signaling pathway is compromised in the brain of autistic subjects (2010) J Neurosci Res, 88, pp. 2641-2647; \n\nShirey, J.K., Brady, A.E., Jones, P.J., Davis, A.A., Bridges, T.M., Kennedy, J.P., Jadhav, S.B., Conn, P.J., A selective allosteric potentiator of the M1 muscarinic acetylcholine receptor increases activity of medial prefrontal cortical neurons and restores impairments in reversal learning (2009) J Neurosci, 29, pp. 14271-14286; \n\nShuang, M., Liu, J., Jia, M.X., Yang, J.Z., Wu, S.P., Gong, X.H., Ling, Y.S., Zhang, D., Family-based association study between autism and glutamate receptor 6 gene in Chinese Han trios (2004) Am J Med Genetics, 131, pp. 48-50; \n\nShytle, R.D., Silver, A.A., Philipp, M.K., McConville, B.J., Sanberg, P.R., Transdermal nicotine for Tourette’s syndrome (1998) Drug Dev Res, 38, pp. 290-298; \n\nSpiridigliozzi, G.A., Heller, J.H., Crissman, B.G., Sullivan-Saarela, J.A., Eelis, R., Dawson, D., Li, J., Kishnani, P.S., Preliminary study of safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series (2007) Am J Med Genet A, 143 A, pp. 1408-1413; \n\nSrivastava, R.K., Agarwal, M., Pundhir, A., (2011) Role of dopenezil in autism: Its conductiveness in psychopharmacology, , Case reports in psychiatry ID563204; \n\nSteinlein, O.K., Bertrand, D., Neuronal nicotinic acetylcholine receptors: From the genetic analysis to neurological diseases (2008) Biochem Pharmacol, 76, pp. 1175-1183; \n\nStuart-Hamilton, I., Griffith, G., Totsika, V., Nash, S., Hastings, R.P., Felce, D., Kerr, M., (2009) The circumstances and support needs of older people with Autism, , Report for the Welsh Assembly Government, Welsh Assembly, Cardiff; \n\nSylvester Vizi, E., Rózsa, B., Mayer, A., Kiss, J.P., Zelles, T., Lendvai, B., Further evidence for the functional role of nonsynaptic nicotinic acetylcholine receptors (2004) Eur J Pharmacol, 500, pp. 499-508; \n\nTaly, A., Corringer, P.-J., Guedin, D., Lestage, P., Changeux, J.-P., Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system (2009) Nat Rev Drug Discov, 8, pp. 733-750; \n\nTata, A.M., Cursi, S., Biagioni, S., Augusti-Tocco, G., Cholinergic modulation of neurofilament expression and neurite outgrowth in chick sensory neurons (2003) J Neurosci Res, 73, pp. 227-234; \n\nTildesley, N.T., Kennedy, D.O., Perry, E.K., Ballard, C.G., Savelev, S., Wesnes, K.A., Scholey, A.B., Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers (2003) Pharmacol Biochem Behav, 75, pp. 669-674; \n\nTildesley, N.T., Kennedy, D.O., Perry, E.K., Ballard, C.G., Wesnes, K.A., Scholey, A.B., Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers (2005) Physiol Behav, 83, pp. 699-709; \n\nTorrao, A.S., Lindstrom, J.M., Britto, L.R., Nicotine and alpha-bungarotoxin modify the dendritic growth of cholinoceptive neurons in the developing chick tectum (2003) Brain Res Dev Brain Res, 143, pp. 115-118; \n\nVasconcelos, M.M., Brito, A.R., Domingues, R.C., da Cruz, L.C., Gasparetto, E.L., Werner, J., Gonc Alves, J.P., Proton magnetic resonance spectroscopy in school-aged autistic children (2008) J Neuroimaging, 18, pp. 288-295; \n\nVilaró, M.T., Palacios, J.M., Mengod, G., Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry (1990) Neurosci Letts, 114, pp. 154-159; \n\nWalker, B.R., Diefenbach, K.S., Parikh, T.N., Inhibition within the nucleus tractus solitarius (NTS) ameliorates environmental exploration deficits due to cerebellum lesions in an animal model for autism (2007) Behav Brain Res, 176, pp. 109-120; \n\nWheless, J.W., Simos, P.G., Butler, I.J., Language dysfunction in epileptic conditions (2002) Semin Pediatr Neurol, 9, pp. 218-228; \n\nWhite, S.W., Oswald, D., Ollendick, T., Scahill, L., Anxiety in children and adolescents with autism spectrum disorders (2009) Clin Psychol Rev, 29, pp. 216-229; \n\nWiker, C., Schilstrom, B., Sandback, C., Wadenberg, M.L., Svensson, T.H., Adjunctive galantamine, but not donepezil, enhances the antipsychotic-like effect of raclopride in rats (2008) Int J Neuropsychopharmacol, 14, pp. 1-6; \n\nWilliams, N.M., Franke, B., Mick, E., Anney, R.J., Freitag, C.M., Gill, M., Thapar, A., Faraone, S.V., Genome-wide analysis of copy number variants in attention deficit hyperactivity disorder: The role of rare variants and duplications at 15q13.3 (2012) Am J Psychiatry, 169, pp. 195-204; \n\nWonnacott, S., Sidhpura, N., Balfour, D.J., Nicotine: From molecular mechanisms to behaviour (2005) Curr Opinion Pharmacol, 5, pp. 53-59; \n\nYasui, D.H., Scoles, H.A., Horike, S., Meguro-Horike, M., Dunaway, K.W., Schroeder, D.I., Lasalle, J.M., 15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain (2011) Hum Mol Genet, 20, pp. 4311-4323; \n\nYoo, J.H., Valdovinos, M.G., Williams, D.C., Relevance of donepezil in enhancing learning and memory in special populations: A review of the literature (2007) J Autism Dev Disord, 37, pp. 1883-1901; \n\nZeisel, S.H., Dietary influences on neurotransmission (1986) Adv Pediatr, 33, pp. 23-47", "hasCitationDuplums" : false, "userChangeableUntil" : "2016-03-05T15:15:53.000+0000", "publishDate" : "2016-03-05T15:15:48.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 8, "ownerInstituteCount" : 29, "directInstituteCount" : 0, "authorCount" : 2, "contributorCount" : 0, "book" : { "otype" : "Book", "mtid" : 30226737, "link" : "/api/publication/30226737", "label" : "S. Hossein Fatemi. The Molecular Basis of Autism. (2015) ISBN:9781493921904", "core" : false, "citation" : false, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Book", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000201, "link" : "/api/subtype/10000201", "label" : "Monograph (Book)", "name" : "Szakkönyv", "nameEng" : "Monograph", "docType" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Book", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "listPosition" : 337, "published" : true, "oldId" : 10000201, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Scientific", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "English", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "title" : "The Molecular Basis of Autism", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 10508654, "link" : "/api/publicationidentifier/10508654", "label" : "ISBN: 9781493921904", "source" : { "otype" : "PlainSource", "mtid" : 122, "link" : "/api/publicationsource/122", "label" : "ISBN", "type" : { "otype" : "PublicationSourceType", "mtid" : 10002, "link" : "/api/publicationsourcetype/10002", "label" : "Egyéb", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "ISBN", "nameEng" : "ISBN", "linkPattern" : "https://www.worldcat.org/search?q=isbn%3A@@@", "publiclyVisible" : true, "published" : true, "oldId" : 122, "snippet" : true }, "idValue" : "9781493921904", "realUrl" : "https://www.worldcat.org/search?q=isbn%3A9781493921904", "published" : false, "snippet" : true } ], "publishedAt" : [ { "otype" : "City", "mtid" : 10367, "link" : "/api/city/10367", "label" : "New York City, United States of America", "partOf" : { "otype" : "Country", "mtid" : 10017, "link" : "/api/country/10017", "label" : "United States of America", "published" : true, "oldId" : 13, "snippet" : true }, "published" : true, "oldId" : 870, "snippet" : true } ], "publishedYear" : 2015, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "published" : true, "snippet" : true }, "hasQualityFactor" : false, "link" : "/api/publication/25477356", "label" : "Mukaetova-Ladinska EB et al. Molecular basis of cholinergic changes in autism spectrum disorders and relevance for treatment interventions. (2015) In: The Molecular Basis of Autism pp. 307-335", "template" : "